Purple Biotech Ltd
PPBT0.583USD
-0.019-3.24%
交易中 （美东）报价延迟15分钟
5.26M总市值
亏损市盈率 TTM
关于 Purple Biotech Ltd 公司
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltd简介
公司代码PPBT
公司名称Purple Biotech Ltd
上市日期Sep 03, 1978
CEOEfron (Gil)
员工数量9
证券类型Depository Receipt
年结日Sep 03
公司地址4 Oppenheimer St.
城市REHOVOT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编7670104
电话97239333121
网址https://purple-biotech.com/
公司代码PPBT
上市日期Sep 03, 1978
CEOEfron (Gil)
Purple Biotech Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Mr. Simcha Rock
Mr. Simcha Rock
Director
Director
--
--
Dr. Gil Ben-Menachem
Dr. Gil Ben-Menachem
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Ido Agmon
Mr. Ido Agmon
Independent Director
Independent Director
--
--
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Mr. Arie Weber
Mr. Arie Weber
Independent Director
Independent Director
--
--
Ms. Revital Stern-Raff
Ms. Revital Stern-Raff
Independent Director
Independent Director
--
--
Mr. Ran Tzror
Mr. Ran Tzror
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Mr. Simcha Rock
Mr. Simcha Rock
Director
Director
--
--
Dr. Gil Ben-Menachem
Dr. Gil Ben-Menachem
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Ido Agmon
Mr. Ido Agmon
Independent Director
Independent Director
--
--
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月31日 周六
更新时间: 1月31日 周六
持股股东
股东类型
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
BNP Paribas Securities Corp. North America
0.12%
其他
89.10%
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
BNP Paribas Securities Corp. North America
0.12%
其他
89.10%
股东类型
持股股东
占比
Corporation
6.51%
Investment Advisor
3.35%
Research Firm
0.77%
Hedge Fund
0.44%
Investment Advisor/Hedge Fund
0.03%
其他
88.90%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
37
426.85K
4.59%
+179.93K
2025Q3
40
355.08K
3.82%
+98.77K
2025Q2
37
55.19K
1.82%
-201.60K
2025Q1
39
103.31K
6.70%
-153.87K
2024Q4
41
133.07K
5.02%
-58.34K
2024Q3
39
222.98K
11.78%
+111.64K
2024Q2
39
147.98K
8.71%
+1.90K
2024Q1
40
184.47K
11.90%
+40.99K
2023Q4
40
174.27K
11.63%
+106.33K
2023Q3
38
64.91K
3.14%
-5.47K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lincoln Alternative Strategies LLC
605.00K
6.51%
+605.00K
--
Sep 04, 2025
Orca Capital GmbH
306.39K
3.3%
+306.39K
--
Sep 07, 2025
Virtu Americas LLC
48.99K
0.53%
+48.99K
--
Sep 30, 2025
Citadel Advisors LLC
41.26K
0.44%
+41.26K
--
Sep 30, 2025
BNP Paribas Securities Corp. North America
11.28K
0.12%
+5.00K
+79.68%
Sep 30, 2025
Morgan Stanley & Co. LLC
11.06K
0.12%
+6.50K
+142.39%
Sep 30, 2025
UBS Financial Services, Inc.
5.95K
0.06%
-17.20K
-74.30%
Sep 30, 2025
GAMMA Investing LLC
2.84K
0.03%
-9.82K
-77.59%
Dec 31, 2025
Rhumbline Advisers Ltd. Partnership
1.08K
0.01%
--
--
Sep 30, 2025
SBI Securities Co., Ltd.
20.00
0%
--
--
Sep 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
公告日期
除权除息日
类型
比率
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
